#carbapenems

[neosciencehub]

Only 8% of Bacterial Infections Managed Properly in India in 2019 @neosciencehub #AMR #Sciencenews #8%BacterialInfections #neosciencehub

Only 8% of Bacterial Infections Managed Properly in India in 2019

[asymchem1]

Carbapenems Manufacturing | Pharma API and Raw Materials by Asymchem

Asymchem specializes in Carbapenems and pharma API manufacturing, providing high-quality raw materials for the pharmaceutical industry. Partner with us for reliable solutions.

Asymchem: Top CDMO for Global Pharma Companies

Discover Asymchem, a top CDMO serving global pharma companies with innovative green solutions, advanced drug development, and manufacturing

[erwinw]

Carbapenems: Definition, Mechanism of Action, Types, Uses, and Side Effects - Laboratory Blog

Carbapenems are a powerful class of antibiotics used to treat severe bacterial infections. Learn about their mechanism of action, types, use

[ptmasterguide]

Carbapenems (Dosage)

In this article, we will discuss Carbapenems (Dosage). So, let’s get started. CarbapenemsThey are structurally similar to penicillins but the sulfur atom in position 1 has been replaced with a carbon atom. They are effective against beta-lactamase producing enterobacteriaceae like Klebsiella pneumoniae, E. coli, Citrobacter sp, Acinobacter sp; Pseudomonas aeruginosa and Alcaligenes sp. They are…

View On WordPress

[newstfionline]

Drug-Resistant Bacteria Spreading in Europe

Associated Press, November 15, 2013

BERLIN--A last-line defense against dangerous infections is becoming less effective in Europe because bacteria are increasingly resistant to drugs.

The European Center for Disease Prevention and Control says countries in Europe are recording increasing numbers of cases where hospital-acquired bacterial infections can't be treated with antibiotics called carbapenems.

The agency said in a report released Friday that five southern European countries saw carbapenem-resistant bloodstream infections with Klebsiella pneumonia bacteria last year, compared with two countries in 2009.

It also said resistant Acinetobacter species have been found in more than a quarter of all infections in eight of 18 reporting countries.

ECDC Director Marc Sprenger called the findings a "very worrying development" for the treatment of diseases that for decades had been thought conquered thanks to antibiotics.